ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
PharmaTher Holdings Ltd (QB)

PharmaTher Holdings Ltd (QB) (PHRRF)

0,15734
0,00
(0,00%)
Fermé 09 Janvier 10:00PM

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
0,15734
Prix Achat
0,15734
Prix Vente
0,15734
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,1228 Plage de 52 semaines 0,32
Cap du marché
Clôture Veille
0,15734
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
393 914
Actions en circulation
88 169 065
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-4,53
Bénéfice par action (BPA)
-0,04
Chiffre d'affairess
-
Bénéfice net
-3,12M

À propos de PharmaTher Holdings Ltd (QB)

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Toronto, Ontario, Can
Fondé
-
PharmaTher Holdings Ltd (QB) est coté dans le secteur Pharmaceutical Preparations de la OTCMarkets avec le ticker PHRRF. Le dernier cours de clôture d'PharmaTher (QB) était de US$0,16. Au cours de la dernière année, les actions de PharmaTher (QB) ont été négociées dans une fourchette de prix de US$ 0,1228 à US$ 0,32.

PharmaTher (QB) compte actuellement 88 169 065 actions en circulation. La capitalisation boursière d'PharmaTher (QB) est de US$13,87 million. PharmaTher (QB) a un ratio cours/bénéfice (ratio PE) de -4.53.

PHRRF Dernières nouvelles

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

 PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch Delivering psilocybin via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles...

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch

 PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch  Focusing on partnership model for MicroDose-MN™ and...

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

 PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products Leading U.S.-based CDMO to manufacture PharmaTher's proprietary ketamine products for FDA Phase 3...

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

 PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome Achieving its second FDA orphan drug designation with ketamine.Building a proprietary...

PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund

 PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund TORONTO, September 21, 2021 -- InvestorsHub NewsWire -- PharmaTher Holdings Ltd. (the...

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

  PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022   10 clinical sites selected to participate in the FDA Phase 2 clinical...

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis

 PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis Focusing on becoming a global leader in prescription-based ketamine productsAdvancing to a Phase...

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

 PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation Strengthens position to become a leader in the intradermal delivery of FDA...

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression

  PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression   Potential for FDA 505(b)(2) regulatory pathway approval and...

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease

  PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease   TORONTO, May 25, 2021 -- InvestorsHub NewsWire -- PharmaTher Holdings...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.00016-0.1015873015870.15750.16480.152278700.15682784CS
4-0.00221-1.385145722340.159550.170.14891597640.15815085CS
12-0.01576-9.104563835930.17310.220.13453939140.16905808CS
260.000140.0890585241730.15720.240750.13452425100.17164186CS
52-0.02266-12.58888888890.180.320.12283223620.18742256CS
156-0.13866-46.84459459460.2960.33280.03682422190.15642575CS
260-0.00716-4.352583586630.16451.390.03683443970.31227331CS

PHRRF - Frequently Asked Questions (FAQ)

What is the current PharmaTher (QB) share price?
The current share price of PharmaTher (QB) is US$ 0,15734
How many PharmaTher (QB) shares are in issue?
PharmaTher (QB) has 88 169 065 shares in issue
What is the market cap of PharmaTher (QB)?
The market capitalisation of PharmaTher (QB) is USD 13,87M
What is the 1 year trading range for PharmaTher (QB) share price?
PharmaTher (QB) has traded in the range of US$ 0,1228 to US$ 0,32 during the past year
What is the PE ratio of PharmaTher (QB)?
The price to earnings ratio of PharmaTher (QB) is -4,53
What is the reporting currency for PharmaTher (QB)?
PharmaTher (QB) reports financial results in CAD
What is the latest annual profit for PharmaTher (QB)?
The latest annual profit of PharmaTher (QB) is CAD -3,12M
What is the registered address of PharmaTher (QB)?
The registered address for PharmaTher (QB) is 82 RICHMOND STREET EAST, TORONTO, ONTARIO, M5C 1P1
What is the PharmaTher (QB) website address?
The website address for PharmaTher (QB) is www.pharmather.com
Which industry sector does PharmaTher (QB) operate in?
PharmaTher (QB) operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
AABVFAberdeen International Inc (PK)
US$ 0,0304
(0,00%)
0
AABKFAareal Bank AG (PK)
US$ 0,00
(0,00%)
0
AABBAsia Broadband Inc (PK)
US$ 0,0308
(0,00%)
0
AAALYAareal Bank AG (PK)
US$ 34,65
(0,00%)
0
AAAIFAlternative Investment Trust (PK)
US$ 0,55
(0,00%)
0
AABVFAberdeen International Inc (PK)
US$ 0,0304
(0,00%)
0
AABKFAareal Bank AG (PK)
US$ 0,00
(0,00%)
0
AABBAsia Broadband Inc (PK)
US$ 0,0308
(0,00%)
0
AAALYAareal Bank AG (PK)
US$ 34,65
(0,00%)
0
AAAIFAlternative Investment Trust (PK)
US$ 0,55
(0,00%)
0
AABVFAberdeen International Inc (PK)
US$ 0,0304
(0,00%)
0
AABKFAareal Bank AG (PK)
US$ 0,00
(0,00%)
0
AABBAsia Broadband Inc (PK)
US$ 0,0308
(0,00%)
0
AAALYAareal Bank AG (PK)
US$ 34,65
(0,00%)
0
AAAIFAlternative Investment Trust (PK)
US$ 0,55
(0,00%)
0
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées